Skip to main content
. 2020 Mar 19;111(5):1692–1698. doi: 10.1111/cas.14366

Figure 1.

Figure 1

Patients with castration‐resistant prostate cancer underwent transrectal ultrasound‐guided injection of GEN0101 (inactivated hemagglutinating virus of Japan envelope [HVJ‐E]) into the prostate on day 1, followed by s.c. injection of HVJ‐E on days 5, 8, and 12. Patients underwent 2 cycles of GEN0101 treatment